Skip to content
Sign in

PBE · ARCA · ETF

Invesco Biotechnology & Genome ETF (PBE) Price, Holdings & Fees

$456.78−0.14%−$0.63End-of-day price as of Oct 9, 2026

Invesco Biotechnology & Genome ETF (PBE) closed at $456.78 on Oct 9, 2026, down 0.14% from the previous close of $457.41.

Share price, past year

1Y +17.73%

52-week range $377.61 – $461.74. Daily closing prices.
Monthly closing prices
Last closing price of each month
DateClose
Oct 9, 2026$456.78
Sep 30, 2026$455.73
Aug 31, 2026$420.94
Jul 31, 2026$412.43
Jun 30, 2026$406.21
May 29, 2026$413.38
Apr 30, 2026$421.95
Mar 31, 2026$422.57
Feb 27, 2026$411.85
Jan 30, 2026$426.30
Dec 31, 2025$377.61
Nov 28, 2025$387.07
Oct 31, 2025$389.79

Key statistics

Expense ratio
0.58%
as of Aug 31, 2025
Net assets
$281.9M
as of Jul 31, 2026
Holdings
33
as of Jul 31, 2026
52-week range
$377.61 – $461.74

Invesco Biotechnology & Genome ETF's expense ratio is 0.58%: $58.00 a year on $10,000 invested.

Holdings

Invesco Biotechnology & Genome ETF held 33 investments worth $281.95M as of Jul 31, 2026. Its largest holding was Invesco Private Prime Fund, at 12.89% of the fund.

Invesco Biotechnology & Genome ETF largest holdings by share of net assets
#Holding% of fundValue
1Invesco Private Prime Fund12.89%$36.34M
2Regeneron Pharmaceuticals, Inc.5.47%$15.43M
3Amgen Inc.5.22%$14.72M
4CareDx, Inc.5.04%$14.21M
5Vertex Pharmaceuticals Inc.4.99%$14.06M
6Invesco Private Government Fund4.97%$14.00M
7Royalty Pharma PLC4.94%$13.93M
8Biogen Inc.4.79%$13.50M
9Gilead Sciences, Inc.4.43%$12.50M
10United Therapeutics Corp.4.08%$11.49M
11Bio-Techne Corp.3.73%$10.53M
12Illumina, Inc.3.51%$9.89M
13Protagonist Therapeutics, Inc.3.40%$9.57M
14Vericel Corp.3.27%$9.21M
15Alnylam Pharmaceuticals, Inc.3.17%$8.93M
16Incyte Corp.3.06%$8.62M
17Repligen Corp.3.04%$8.57M
18Acadia Pharmaceuticals Inc.3.02%$8.52M
19Halozyme Therapeutics, Inc.2.98%$8.41M
20Qiagen N.V.2.89%$8.16M
21BioMarin Pharmaceutical Inc.2.82%$7.95M
22Neurocrine Biosciences, Inc.2.66%$7.50M
23Exelixis, Inc.2.64%$7.43M
24BioCryst Pharmaceuticals, Inc.2.63%$7.43M
25Veracyte, Inc.2.60%$7.34M

Top 25 of 33 holdings, as of Jul 31, 2026. Percentages are of the fund's net assets.

What the fund owns

Invesco Biotechnology & Genome ETF holdings by asset type
Asset type% of fund
Stocks100.05%
Cash and short-term investments17.93%
Invesco Biotechnology & Genome ETF holdings by country, largest 4
Country% of fund
United States108.58%
United Kingdom4.94%
Netherlands2.89%
Cayman Islands1.56%

Shares of net assets from the fund's N-PORT report. Funds that borrow can add up to more than 100%, with borrowing (such as repurchase agreements) shown as a negative share.

Monthly total returns

Over the 3 months to Jul 31, 2026, Invesco Biotechnology & Genome ETF's total return was +13.60%, as reported to the SEC.

Invesco Biotechnology & Genome ETF monthly total returns
MonthTotal return
Jul 31, 2026−0.16%
Jun 30, 2026+7.97%
May 31, 2026+5.38%

The fund's own total returns as reported to the SEC (N-PORT), including reinvested distributions. Not the sample prices above.

Fund profile

Name
Invesco Biotechnology & Genome ETF
Ticker
PBE
Exchange
ARCA
Fund type
ETF
Trust
INVESCO EXCHANGE-TRADED FUND TRUST
SEC series ID
S000003026
SEC CIK
0001209466
Fractional shares
Yes

Recent SEC filings

Shareholder reports and prospectuses are filed by INVESCO EXCHANGE-TRADED FUND TRUST, the trust behind Invesco Biotechnology & Genome ETF, and cover all of its funds.

Frequently asked questions

What is PBE's price?

Invesco Biotechnology & Genome ETF (PBE) closed at $456.78 on Oct 9, 2026, down 0.14% from the previous close of $457.41.

What is PBE's expense ratio?

Invesco Biotechnology & Genome ETF's expense ratio is 0.58%: $58.00 a year on $10,000 invested.

What does PBE hold?

Invesco Biotechnology & Genome ETF held 33 investments worth $281.95M as of Jul 31, 2026. Its largest holding was Invesco Private Prime Fund, at 12.89% of the fund. Its five largest holdings were Invesco Private Prime Fund, Regeneron Pharmaceuticals, Inc., Amgen Inc., CareDx, Inc., Vertex Pharmaceuticals Inc..

How has PBE performed?

Over the 3 months to Jul 31, 2026, Invesco Biotechnology & Genome ETF's total return was +13.60%, as reported to the SEC.

Sources and methodology

Holdings, net assets and monthly returns come from the fund's N-PORT filing with the SEC, as of Jul 31, 2026 (filed Sep 28, 2026). The expense ratio is from the fund's prospectus or shareholder report, as of Aug 31, 2025. Prices are generated sample data for development. Data sources and disclosures